<DOC>
	<DOCNO>NCT00416962</DOCNO>
	<brief_summary>This study design assess safety pharmacokinetic effect oseltamivir administration alone combination amantadine healthy volunteer .</brief_summary>
	<brief_title>Safety Pharmacokinetic Effects Oseltamivir Alone Combination With Amantadine</brief_title>
	<detailed_description />
	<mesh_term>Oseltamivir</mesh_term>
	<mesh_term>Amantadine</mesh_term>
	<criteria>Healthy male female subject age 18 45 year , good health determine past medical history , physical examination , vital sign , electrocardiogram , laboratory test Vital sign within follow range : oral body temperature 35.0 37.5°C systolic blood pressure 90 140 mm Hg diastolic blood pressure 50 90 mm Hg pulse rate 40 90 bpm Female subject child bear potential must use doublebarrier local contraception ( example , intrauterine device plus condom , spermicidal gel plus condom ) surgically sterilize least 6 month prior study start , supportive clinical documentation OR Postmenopausal woman must regular menstrual bleeding least 1 year prior inclusion . Body mass index must within 18 30 kg/m2 . Subjects must weigh least 50 kg . Smokers ( use tobacco product previous 3 month ) . Smokers define report tobacco use urine cotinine great 500 ng/mL Female subject pregnant lactate Participation clinical investigation involve medical intervention within 4 week prior study start . Donation loss ≥ 400 mL blood within 8 week prior study start , longer required local regulation . Significant illness within 2 week study start . A past personal close family medical history clinically significant ECG abnormality prolong QTinterval syndrome . History autonomic dysfunction ( example , history fainting ) . History acute chronic bronchospastic disease ( include asthma chronic obstructive pulmonary disease , treat untreated ) , History clinically significant drug allergy history atopic allergy ( asthma , urticaria , eczematous dermatitis ) . A known hypersensitivity study drug similar drug . Any surgical medical condition might significantly alter absorption , distribution , metabolism excretion drug , may jeopardize subject case participation study , include bowel , gastrointestinal , renal , pancreatic , hepatic , hematological , immunological , neurological disorder . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>Oseltamivir , amantidine , Symmetrel , Tamiflu</keyword>
</DOC>